-
How about reproducing local cases in many places across the country?
Time of Update: 2021-11-01
How about reproducing local cases in many places across the country? How to deal with it? How about reproducing local cases in many places across the country? How to deal with it? H
-
Notice on Public Solicitation of Opinions on the "List of Reference Preparations of Chemical Generic Drugs (The 51st Batch)" (Draft for Solicitation of Comments)
Time of Update: 2021-11-01
During the period of publicity, please provide feedback to the Drug Evaluation Center through the "Suspicious Variety Application for Reference Preparation" module under the application platform for the selection of reference preparations.
docx 2 Application Form for Objection to Chemical Generic Drug Reference Preparation.
-
National Health Commission: The epidemic is currently in a stage of rapid development
Time of Update: 2021-11-01
National Health Commission: The current epidemic is in a stage of rapid development, and the number of cases detected in the next few days will continue to increase.
-
On October 24, 39 newly diagnosed cases were confirmed, including 35 in the local area
Time of Update: 2021-11-01
As of 24:00 on October 24, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are 573 confirmed cases (including 20 severe cases), a total of 91588 cured and discharged cases, and a total of 4636 deaths.
-
China's health level ranks fifth among upper-middle-income countries in the world
Time of Update: 2021-11-01
The Healthy China Index launched by the Xinhua News Agency News Information Center and the Shanghai Huaxia Social Development Research Institute is based on the health resources, health services, health protection, health environment, and health level.
-
Shanghai releases policy recommendations for improving the Alzheimer's disease prevention and control system
Time of Update: 2021-11-01
According to the "Policy Recommendations", a series of progress has been made in the prevention and control of Alzheimer's disease in China, but the incidence rate continues to increase; the burden on society and families is increasing; the timeliness of diagnosis is insufficient, and the golden window period is easy to miss; society The guarantee mechanism needs to be further improved and other issues .
-
Russian Institute of Virology Releases Latest Photos of Delta Mutant Strain
Time of Update: 2021-11-01
Russian Institute of Virology Releases Latest Photos According to a report by RIA Novosti, on the 25th local time, the Russian National Science Center for Vector Virology and Biotechnology announced for the first time a photo of the new coronavirus mutant strain "Delta", which was taken by an electron microscope .
-
Experts break space barriers to realize a new model of off-site diagnosis and treatment of birth defects
Time of Update: 2021-11-01
Relying on this alliance, Huang Hefeng’s team has established a big data platform for related birth defects, drawn a map of common recessive pathogenic genes in the Chinese population, a new map of perinatal structural abnormalities, and a map of chromosome variation in the newborn population, providing detailed information for the diagnosis and treatment of birth defects.
-
Pfizer, Roche, and Huizhi's structural changes attract attention!
Time of Update: 2021-11-01
Pfizer China replicates the global structure There are three main points of China's organizational reform announced by Pfizer this time: First, six independent business units were established, namely hospital emergency, tumor, rare diseases, inflammation and immunity, vaccines, and broad markets .
-
National procurement has landed, the two provinces do not engage in "one size fits all", and the allocation ratio of unselected varieties in Shanghai is about 20%
Time of Update: 2021-11-01
On October 14th, Jiangsu Province issued the "Notice on Doing a Good Job in the Implementation of the Fifth Batch of Nationally Organized Drug Centralized Procurement Results", clarifying that the procurement price will be switched from the provincial platform at 24:00 on October 25; 24:00 on October 31 Start execution .
-
Levofloxacin intermediates and APIs of East Asia Pharmaceuticals obtained EU registration certificate
Time of Update: 2021-10-23
On September 23, East Asia Pharmaceuticals announced that it had recently received the "Certificate of Applicability of the European Pharmacopoeia" issued by the European Medicines Quality Agency.
Levofloxacin intermediates and APIs have obtained EU registration certificates .
-
Plymouth's best-selling injections enter the UK!
Time of Update: 2021-10-23
On September 22, Puli Pharmaceuticals issued an announcement stating that it had recently received a marketing authorization for bivalrudine for injection issued by the British Medicines and Health Products Administration (MHRA), which indicated that the company has the qualification to sell the product in the UK .
-
Zhenhe Technology joins hands with Imona Medical to jointly develop mRNA tumor vaccines
Time of Update: 2021-10-23
Zhenhe Technology and Imona Medical will work together to break through technical bottlenecks, accelerate product development, and realize tumor vaccines based on tumor neoantigen + mRNA technology platform as soon as possible to serve the majority of tumor patients .
-
Four domestically produced PD-1s, ten new indications, and medical insurance negotiations are about to fall this year
Time of Update: 2021-10-23
In addition to the two included in medical insurance, BeiGene announced on January 14 this year that NMPA has approved its anti-PD-1 antibody tislelizumab combined with two chemotherapy regimens for the treatment of first-line advanced squamous non-small cell lung cancer (NSCLC).
-
Yahong Pharma appoints Dr. Chen Yu as Vice President of Biological Research and Head of Translational Medicine Research of New Drug Discovery Department
Time of Update: 2021-10-23
Chen Yu will be responsible for and lead the biological research team to develop cutting-edge biotherapeutic technologies, new targets and mechanism research, and accelerate the promotion of new drug discovery projects .
-
Oncolytic virus and PD-L1 inhibitor Roche reach clinical cooperation
Time of Update: 2021-10-23
Arthur Kuan, CEO of CG Oncology, said: "We are very pleased to combine the lead oncolytic immunotherapy CG0070 with atelizumab to evaluate their potential synergy in cancer in this important clinical trial .
-
Korsuva receives FDA approval to treat moderate to severe itching in patients with chronic kidney disease
Time of Update: 2021-10-23
▲Korsuva reached the primary endpoint in two key Phase 3 clinical trials (Image source: Cara Therapeutics official website)Korsuva is a "first-in-class" κ opioid receptor (KOR) agonist, which directly inhibits the activity of peripheral neurons that produce itching, so it can be used to relieve itching due to many reasons .
Retrieved August 23, 2021, from https:// news-release/2021/08/23/2285085/29236/en/Cara-Therapeutics-and-Vifor-Pharma-announce-US-FDA-approval-of-KORSUVA-difelikefalin-injection-for-the-treatment-of- moderate-to-severe-pruritus-in-hemodialysis-patients.
-
Drug Administration of Ningxia Hui Autonomous Region: Cancellation of the drug business licenses for the headquarters of two chain pharmacies
Time of Update: 2021-10-23
Drug Administration Notice, the two chain pharmacy headquarters will sell the certificateDrug Administration Notice, the two chain pharmacy headquarters will sell the certificateOn September 26, the Drug Administration of Ningxia Hui Autonomous Region issued the "Notice on the cancellation of the Pharmaceutical Business License of Guyuan Ruihetang Pharmaceutical Chain Sales Co.
-
Where is the next growth point in the sales of Bojian Alzheimer's disease new drug?
Time of Update: 2021-10-23
Due to the slow use of the Alzheimer's disease drug Aduhelm, Biogen may suffer a loss of US$20 billion .
Do not enter: Biogen reps banned from DC-area neurology clinics over controversial Alzheimer's drug Aduhelm
-
Anke Biological Holding Subsidiary ZG033 Injection Drug Registration Application Accepted
Time of Update: 2021-10-23
At present, monoclonal antibodies and double antibodies targeting 4-1BB have shown their anti-tumor efficacy in preclinical or clinical trials.
